Evidence map›Paper›PMID 41408327›Full record

ArticleJournal of hematology & oncology2025

Updated data of CLL1 CAR-T cell therapy in adult patients with relapsed/refractory acute myeloid leukemia.

Xiaomei Zhang, Wenyi Lu, Wenjun Zhang, Xiaoyuan He, Yu Zhang, Xin Jin, Meng Zhang, Yingshuai Wang, Xuwen Guan, Rui Zhang and 13 more

Abstract readClinical Trial, Phase ILetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hematology & oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Xiaomei Zhang *Tianjin First Central Hospital, The First Affiliated Central Hospital of Nankai University, The First Central Clinical College of Tianjin Medical University, No. 2, West Baoshan Road, Xiqing District, Tianjin, China.
Wenyi Lu *Department of Hematology, Institute of Hematology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, 475001, China.
Wenjun Zhang *Department of Hematology, Tongji Hospital, School of Medicine, Tongji University, No. 389 Xincun Road, Shanghai, China.
Xiaoyuan HeTianjin First Central Hospital, The First Affiliated Central Hospital of Nankai University, The First Central Clinical College of Tianjin Medical University, No. 2, West Baoshan Road, Xiqing District, Tianjin, China.
Yu ZhangTianjin First Central Hospital, The First Affiliated Central Hospital of Nankai University, The First Central Clinical College of Tianjin Medical University, No. 2, West Baoshan Road, Xiqing District, Tianjin, China.
Xin JinSir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310058, China.
Meng ZhangDepartment of Hematology, Beijing Children's Hospital, Beijing, 100045, China.
Yingshuai WangDepartment of Medicine III, LMU University Hospital, LMU Munich, 80539, Munich, Germany.
Xuwen GuanTianjin First Central Hospital, The First Affiliated Central Hospital of Nankai University, The First Central Clinical College of Tianjin Medical University, No. 2, West Baoshan Road, Xiqing District, Tianjin, China.
Rui ZhangTianjin First Central Hospital, The First Affiliated Central Hospital of Nankai University, The First Central Clinical College of Tianjin Medical University, No. 2, West Baoshan Road, Xiqing District, Tianjin, China.
Bing WangTianjin First Central Hospital, The First Affiliated Central Hospital of Nankai University, The First Central Clinical College of Tianjin Medical University, No. 2, West Baoshan Road, Xiqing District, Tianjin, China.
Hairong LyuTianjin First Central Hospital, The First Affiliated Central Hospital of Nankai University, The First Central Clinical College of Tianjin Medical University, No. 2, West Baoshan Road, Xiqing District, Tianjin, China.
Xia XiaoTianjin First Central Hospital, The First Affiliated Central Hospital of Nankai University, The First Central Clinical College of Tianjin Medical University, No. 2, West Baoshan Road, Xiqing District, Tianjin, China.
Xue BaiTianjin First Central Hospital, The First Affiliated Central Hospital of Nankai University, The First Central Clinical College of Tianjin Medical University, No. 2, West Baoshan Road, Xiqing District, Tianjin, China.
Yedi PuTianjin First Central Hospital, The First Affiliated Central Hospital of Nankai University, The First Central Clinical College of Tianjin Medical University, No. 2, West Baoshan Road, Xiqing District, Tianjin, China.
Juanxia MengTianjin First Central Hospital, The First Affiliated Central Hospital of Nankai University, The First Central Clinical College of Tianjin Medical University, No. 2, West Baoshan Road, Xiqing District, Tianjin, China.
Haibo ZhuTianjin First Central Hospital, The First Affiliated Central Hospital of Nankai University, The First Central Clinical College of Tianjin Medical University, No. 2, West Baoshan Road, Xiqing District, Tianjin, China.
Zhao WangTianjin First Central Hospital, The First Affiliated Central Hospital of Nankai University, The First Central Clinical College of Tianjin Medical University, No. 2, West Baoshan Road, Xiqing District, Tianjin, China.
Huan ZhangTianjin First Central Hospital, The First Affiliated Central Hospital of Nankai University, The First Central Clinical College of Tianjin Medical University, No. 2, West Baoshan Road, Xiqing District, Tianjin, China.
Cuicui LyuTianjin First Central Hospital, The First Affiliated Central Hospital of Nankai University, The First Central Clinical College of Tianjin Medical University, No. 2, West Baoshan Road, Xiqing District, Tianjin, China.
Hongkai ZhangSchool of life Sciences, Nankai University, No.94 Weijin Road, Nankai District, Tianjin, China. hongkai@nankai.edu.cn.
Aibin LiangDepartment of Hematology, Tongji Hospital, School of Medicine, Tongji University, No. 389 Xincun Road, Shanghai, China. lab7182@tongji.edu.cn.
Mingfeng ZhaoTianjin First Central Hospital, The First Affiliated Central Hospital of Nankai University, The First Central Clinical College of Tianjin Medical University, No. 2, West Baoshan Road, Xiqing District, Tianjin, China. mingfengzhao@sina.com.

Funding

Beijing Natural Science Foundation 7254351major special project on public health science and technology in Tianjin 24ZXGZSY00120National Natural Sciences Foundation of China 82570274National Natural Sciences Foundation of China 82570277the Science and Technology Project of Tianjin Municipal Health Committee TJWJ2022QN030the Science and Technology Project of Tianjin Municipal Health Committee TJWJ2022XK018the Science and Technology Project of Tianjin Municipal Health Committee TJWJ2023QN027the Science and Technology Project of Tianjin Municipal Health Committee TJWJ2023XK010the Science and Technology Project of Tianjin Municipal Health Committee TJWJ2024QN040the Science and Technology Project of Tianjin Municipal Health Committee TJWJ2025MS011Tianjin Key Clinical Specialty Construction Project and Tianjin Key Medical Discipline Construction Project TJYXZDXK-3-001A-004Tianjin Key Medical Discipline (Specialty) Construction Project TJWJ2023XK010
6 · The paper itself

Abstract

CLL1-targeted chimeric antigen receptor T (CAR-T) cell therapy has shown clinically meaningful activity in relapsed/refractory acute myeloid leukemia (R/R AML). This updated phase I study enrolled 38 adults with R/R AML to evaluate the safety and efficacy of this treatment according to the prespecified protocol. Treatment-related adverse events included grade 3/4 cytokine release syndrome (CRS) in 17 patients (44.74%) and grade 4 immune effector cell-associated neurotoxicity syndrome (ICANS) in 1 patient (2.63%). Persistent cytopenia (all grades) was observed in all patients, with a median time to neutrophil recovery of 45 days. At a median follow-up of 24.87 months, the objective response rate (ORR) was 73.68% (28/38), and the minimal residual disease-negative complete response rate (MRD

Indexed as

Immunotherapy, AdoptiveLeukemia, Myeloid, AcuteReceptors, Chimeric AntigenAdultAgedCytokine Release SyndromeFemaleHumansMaleMiddle AgedYoung AdultReceptors, Chimeric AntigenChimeric antigen receptor t cellsC-type lectin-like moleculeRelapsed/refractory acute myeloid leukemia

Identifiers

PMID41408327
PMCPMC12713261

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.